This page lists the SEC filings reported by RA Capital Management.
| Type | Filed | Filer | Subject | Shares Owned | Percent Owned | |
|---|---|---|---|---|---|---|
| SC 13G | 2024-04-25 | RA CAPITAL MANAGEMENT, L.P. | Protara Therapeutics, Inc. | 2,073,075 | 10.0% | EDGAR |
| SC 13G | 2024-04-15 | RA CAPITAL MANAGEMENT, L.P. | Surrozen, Inc./DE | 323,662 | 10.0% | EDGAR |
| SC 13D/A | 2024-04-12 | RA CAPITAL MANAGEMENT, L.P. | Eliem Therapeutics, Inc. | 13,189,736 | 47.5% | EDGAR |
| SC 13G | 2024-04-12 | RA CAPITAL MANAGEMENT, L.P. | Boundless Bio, Inc. | 2,180,631 | 9.8% | EDGAR |
| SC 13D/A | 2024-04-11 | RA CAPITAL MANAGEMENT, L.P. | Acrivon Therapeutics, Inc. | 8,359,102 | 27.1% | EDGAR |
| SC 13G | 2024-04-11 | RA CAPITAL MANAGEMENT, L.P. | CervoMed Inc. | 825,373 | 10.0% | EDGAR |
| SC 13G | 2024-04-04 | RA CAPITAL MANAGEMENT, L.P. | Dyne Therapeutics, Inc. | 5,213,661 | 6.4% | EDGAR |
| SC 13G | 2024-04-01 | RA CAPITAL MANAGEMENT, L.P. | SERA PROGNOSTICS, INC. | 2,047,221 | 6.5% | EDGAR |
| SC 13D/A | 2024-03-29 | RA CAPITAL MANAGEMENT, L.P. | ARS Pharmaceuticals, Inc. | 10,860,977 | 11.3% | EDGAR |
| SC 13D/A | 2024-03-29 | RA CAPITAL MANAGEMENT, L.P. | Nkarta, Inc. | 13,848,371 | 18.9% | EDGAR |
| SC 13G | 2024-03-29 | RA CAPITAL MANAGEMENT, L.P. | Alto Neuroscience, Inc. | 1,385,491 | 5.2% | EDGAR |
| SC 13D | 2024-03-28 | RA CAPITAL MANAGEMENT, L.P. | LENZ Therapeutics, Inc. | 4,250,856 | 16.6% | EDGAR |
| SC 13G | 2024-03-25 | RA CAPITAL MANAGEMENT, L.P. | CYBIN INC. | 58,139,535 | 7.7% | EDGAR |
| SC 13G | 2024-03-25 | RA CAPITAL MANAGEMENT, L.P. | Regulus Therapeutics Inc. | 6,250,000 | 9.5% | EDGAR |
| SC 13D/A | 2024-03-18 | RA CAPITAL MANAGEMENT, L.P. | Eliem Therapeutics, Inc. | 13,179,181 | 47.5% | EDGAR |
| SC 13D/A | 2024-03-11 | RA CAPITAL MANAGEMENT, L.P. | PepGen Inc. | 10,695,135 | 33.1% | EDGAR |
| SC 13D/A | 2024-03-06 | RA CAPITAL MANAGEMENT, L.P. | 89bio, Inc. | 14,254,298 | 14.8% | EDGAR |
| SC 13D/A | 2024-03-06 | RA CAPITAL MANAGEMENT, L.P. | Janux Therapeutics, Inc. | 10,593,395 | 20.0% | EDGAR |
| SC 13D/A | 2024-02-27 | RA CAPITAL MANAGEMENT, L.P. | Connect Biopharma Holdings Ltd | 0 | 0.0% | EDGAR |
| SC 13G | 2024-02-26 | RA CAPITAL MANAGEMENT, L.P. | Larimar Therapeutics, Inc. | 6,045,351 | 9.5% | EDGAR |
- Form 13F-HR
- The 13F-HR report is filed quarterly to report securities held by the filer that fall under the SEC's 13F rules.
- Form SC 13D/G
- Reported by persons and groups who own 5% or more of any class of a company's outstanding shares. If the ownership changes by 1% or more, an amendment must be filed.
- Form 3, 4, and 5
- Form 3, 4, and 5 reports are filed to report insider transactions by company officers and directors, and any beneficial owners of more than ten percent of a company's shares. Form 3 is the initial report that must be filed when a person becomes an officer, director, or beneficial owner. Form 4 reports are used to report changes in ownership, while the Form 5 report is used for reporting transactions that should have been reported earlier in a Form 4 filing.